Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
UCB Pharma (Japan)
h-index: 13
Total citations: 732
Total papers: 55
Homepage:
https://www.ucbjapan.com
Recent papers from UCB Pharma (Japan)
A robust meta-analytic approach for evaluating regional treatment effect in a multi-regional clinical trial
Journal of Biopharmaceutical Statistics · 2026
Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trial
Epilepsy & Behavior Reports · 2026
Early transcriptomic signature of the immune response to rVSV∆G-ZEBOV-GP vaccination in Gabonese children
npj Vaccines · 2026
Evaluation of an EAST Nudge‐Based Oral Health Promotion Leaflet for Workers: A Six‐Month Randomized Controlled Trial
International Journal of Dental Hygiene · 2026
Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan
Dermatology and Therapy · 2026
Treatment Patterns in Patients with Late-Onset Myasthenia Gravis in Japan: An Insurance Claims Database Study
Drugs - Real World Outcomes · 2026
Bioequivalence and Safety Assessment of Brivaracetam Dry Syrup Compared With Tablets in Healthy Japanese Participants: Results From Two Randomized Single‐ and Multiple‐Dose Trials
Clinical Pharmacology in Drug Development · 2026
Treatment Patterns in Hospitalized Hip Fracture Patients: An Interrupted Time-Series Analysis Around the New Fee for Secondary Fracture Prevention in Japan
Rheumatology and Therapy · 2026
Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan
Frontiers in Neurology · 2025
Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial
Advances in Therapy · 2025
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
Dermatology and Therapy · 2025
Gut Microbiome Composition Changes During Insomnia Treatment with Lemborexant
Nature and Science of Sleep · 2025
Mechanistic insights from the atomic-level quaternary structure of short-lived GPCR oligomers of the human secretin receptor in live cells
Communications Biology · 2025
Safety, Tolerability, and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients with Focal-Onset Seizures: Interim Analysis of a Phase 3 Open-Label Extension Trial
Advances in Therapy · 2025
Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study
BMJ Open · 2025
Clinical challenges in narcolepsy: From delayed diagnosis to daytime function impairments during treatment
Sleep Medicine · 2025
Risk factors affecting quality of life in children with epilepsy and their caregivers: A secondary analysis of a cross-sectional online survey in Japan
Epilepsy & Behavior · 2025
Management of psoriasis in women 18 to 45 years of age in Australia and Japan: insights from patient and dermatologist surveys
International Journal of Women’s Dermatology · 2025
Pharmacovigilance Pregnancy Data in a Population of Japanese Patients With Chronic Inflammatory Disease Exposed to Certolizumab Pegol
International Journal of Rheumatic Diseases · 2025
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil
Expert Opinion on Drug Metabolism & Toxicology · 2024